Form 4: Terns Pharmaceuticals CFO Andrew Gengos Acquires 750,000 Stock Options
SEC Form 4 Filing
Andrew Gengos, CFO of Terns Pharmaceuticals, reports the acquisition of 750,000 stock options with a vesting schedule commencing on February 24, 2025.
Summary
- On February 24, 2025, Andrew Gengos, the Chief Financial Officer of Terns Pharmaceuticals, acquired 750,000 stock options.
- The exercise price of these options is $3.73.
- The options vest over a four-year period, starting with 25% vesting on the first anniversary of February 24, 2025, and the remainder vesting monthly thereafter.
- The options expire on February 23, 2035.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock option grants, neither particularly positive nor negative.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities by a company insider. It is common for executives to receive stock options as part of their compensation packages.
Stakeholder Impact
- The granting of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 02/24/2025 | Date of transaction and Vesting Commencement Date for stock options. |
| 02/25/2025 | Date of report submission. |
| 02/23/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.